Some 30 of the most promising drug discovery projects from universities and small- and mid-sized companies will have a better chance of reaching patients thanks to NEOMED. This newest CECR is building on the early success of the NEOMED Institute in Montréal, a multi-tenant, open-access life sciences R&D facility created in 2012. NEOMED will identify promising drug discovery projects and then rely on contract research organizations to advance the research to early proof of concept in humans. At that stage of development, projects can be out-licensed to pharma industry partners, form the basis for the creation of solid spinoffs, or be used to consolidate the commercial performance of existing companies.